Bioscience

Wallingford-based X9 Inc. raised nearly $13.7 million to develop an AI-guided device that uses ultrasound to help insert dialysis needles, receiving FDA approval for its ultrasound-only version in October.

BioXcel Therapeutics Inc. has named longtime biopharmaceutical executive Mark Pavao as its acting chief commercial officer, choosing an industry veteran to lead its efforts to expand the reach of its drug IGALMI.

Veradermics Inc., a New Haven-based biopharmaceutical startup developing an oral treatment for pattern hair loss, has filed for an initial public offering.

New Haven-based Biohaven Ltd. said Tuesday it expects to raise about $125 million via the sale of common shares to Janus Henderson Investors.

The company said the move is primarily aimed at addressing Nasdaq listing requirements.

Boehringer, one of Connecticut’s largest pharmaceutical employers, has reached an agreement with the U.S. government to lower some drug costs and expand its U.S. operations.

Ryan Coles leads a Hartford-based company vying to create a smart contact lens, a venture that requires...

Shelton biotech Intensity Therapeutics paused its Phase 3 cancer trial after running low on cash. The company needs $30M to finish testing INT230-6, an injectable drug that attacks tumors directly.

New Haven-based Veradermics raised $150M to advance its oral minoxidil pill for hair loss into Phase 3 trials. The biotech, founded by dermatologist Reid Waldman, is recruiting 1,500 patients for the study.

Fungal pathogens are among the most economically damaging threats to global crop production, with yield losses in the billions of dollars.